Related Experiment Videos
Intermittent high-dose melphalan/prednisone vs continuous low-dose melphalan treatment in multiple myeloma
European Journal of Cancer & Clinical Oncology
|April 1, 1983
Summary
Intermittent high-dose melphalan/prednisone (MP) therapy improved response rates and survival for multiple myeloma patients compared to continuous low-dose melphalan (M). Early-stage patients particularly benefited from the MP regimen.
Area of Science:
- Hematology
- Oncology
- Clinical Pharmacology
Background:
- Multiple myeloma is a hematologic malignancy characterized by uncontrolled plasma cell proliferation.
- Treatment strategies aim to improve patient survival and quality of life.
- Optimizing chemotherapy regimens is crucial for managing multiple myeloma.
Purpose of the Study:
- To compare the efficacy of intermittent high-dose melphalan/prednisone (MP) versus continuous low-dose melphalan (M) in newly diagnosed multiple myeloma patients.
- To evaluate the impact of treatment on response rates, survival, and clinical stage.
Main Methods:
- A randomized controlled trial involving 219 patients with newly diagnosed multiple myeloma.
- Patients were assigned to either intermittent high-dose MP or continuous low-dose M.
- Median observation time was 59 months.
Main Results:
- The MP group showed a significantly higher response rate (45%) compared to the M group (31%).
- Median survival was longer in the MP group (36 months) than in the M group (29 months).
- Stages I and II myeloma patients demonstrated significantly better median and 5-year survival rates with MP treatment.
Conclusions:
- Intermittent high-dose melphalan/prednisone is a more effective treatment strategy for newly diagnosed multiple myeloma than continuous low-dose melphalan.
- Treatment response is strongly associated with improved survival outcomes.
- Early-stage multiple myeloma patients experience significant survival benefits from the MP regimen.